Pharma Business Week articles from July 2004

Pharma Business Week archives from July 2004

Phase III trial data suggest some lung cancer patients may benefit from RSR13.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Allos Therapeutics, Inc., (ALTH) announced that a retrospective analysis of the results from its phase III trial of the investigational radiation sensitizer RSR13 (efaproxiral) in patients with brain...

Companies ink agreement to make optimized beta interferon for clinical trials.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Maxygen, Inc., (MAXY) and Biovitrum, AB, announced the signing of an agreement for the manufacture of Maxygen's improved interferon beta material for phase I and phase II clinical development. ...

Regulatory submission of pancreatic cancer therapy begins in Switzerland.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Aphton (APHT) announced that it has begun submission of regulatory documentation to the Swiss Agency for Therapeutic Products (Swissmedic), the regulatory authority in Switzerland, for the registration...

European survey identifies need for more education surrounding clinical trials.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Forty-two percent of Europeans surveyed would be more likely to participate in a clinical research study if they were aware of the measures in place to protect them. These findings come from more...

Antipsychotic Abilify (aripiprazole) approved for marketing in Europe.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Bristol-Myers Squibb Company (BMY) and Otsuka Pharmaceutical Co., Ltd., announced that the European Commission has granted marketing authorization for Abilify (aripiprazole), an antipsychotic...

Preliminary phase II alfimeprase results in trial reported.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Nuvelo, Inc., (NUVO) announced the presentation of preliminary clinical data from the first 87 patients in its phase II alfimeprase trial in acute peripheral arterial occlusion (PAO), showing there was...

Tocosol Paclitaxel shows anti-tumor activity in advanced cancer, well tolerated.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Sonus Pharmaceuticals, Inc., (SNUS) presented ongoing results from three phase IIa clinical studies of Tocosol Paclitaxel in poster sessions during the Annual Meeting of the American Society of Clinical...

Study evaluates Xcytrin plus Taxotere for advanced refractory tumors.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Pharmacyclics, Inc., (PCYC) announced encouraging early findings from a phase I clinical trial of Xcytrin (motexafin gadolinium) Injection, the company's lead cancer therapeutic candidate, in...

Decitabine well tolerated with chemotherapy for advanced solid tumors.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- SuperGen, Inc., (SUPG) announced that a phase I study of Dacogen (decitabine) for injection, the company's investigational cancer treatment for myelodysplastic syndromes (MDS), demonstrated positive...

Positive preliminary results announced for VEGF Trap study in solid tumors.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Regeneron Pharmaceuticals, Inc., (REGN) announced positive preliminary results from the phase I trial for the company's vascular endothelial growth factor (VEGF) Trap in patients with advanced solid...

Global aesthetic market study highlights new business opportunities.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- The booming aesthetic procedure market is generating a wide array of new business development opportunities, according to a new research report released by Medical Insight, Inc. Light-based...

Cerebrospinal fluid sample bank launched.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- PrecisionMed Inc. announced the launch of its new PrecisionMed Sample Bank collection of cerebrospinal fluid (CSF), DNA, RNA, plasma, serum, and urine from 100 normal subjects to act as controls for an...

Company to initiate AEOL 10150 safety studies directly in patients with ALS.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Incara Pharmaceuticals Corp. (ICRA) announced that following discussions with the U.S. Food and Drug Administration (FDA), it was mutually agreed Incara would quickly revise the phase I (safety)...

Aranesp corrects chemotherapy-induced anemia when dosed once every 3 weeks.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Amgen Inc. (AMGN) announced results of a new study demonstrating that Aranesp (darbepoetin alfa) dosed once every 3 weeks achieved and maintained the target hemoglobin levels recommended by clinical...

Anthrax antibody profiled in medical journal.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Avanir Pharmaceuticals' (AVN) anti-anthrax monoclonal antibodies protected rats from lethal anthrax toxins, according to a study published in the peer-reviewed Journal of Immune Based Therapies and...

Pharmaceutical company receives FDA approval of ciprofloxacin tablets.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Teva Pharmaceutical Industries Ltd. (TEVA) announced that the U.S. Food and Drug Administration has granted final approval for the company's Abbreviated New Drug Application for Ciprofloxacin Tablets...

MediciNova acquires phase II anxiety compound.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- MediciNova, Inc., a privately held specialty pharmaceutical company, announced the acquisition of a potential treatment for anxiety disorders from Mitsubishi Pharma Corp. of Japan. The compound,...

Long-term relief from arthritis could evolve from B-cell targeted treatments.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Long-term relief for arthritis sufferers could be one step closer, thanks to a study of B-cell-targeted therapy. The study from University College London (UCL) reveals a major but hitherto poorly...

New target to control asthma identified.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- A new target for control of early-stage asthma has been identified by McGill University professor Qutayba Hamid working as part of a team whose landmark study has now been published. Hamid heads a...

Prevalence, exposure to mouse allergen may contribute to asthma.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Mouse allergen has a widespread presence in U.S. homes and may contribute to the development of asthma, according to a study featured in the June 2004 Journal of Allergy and Clinical Immunology (JACI)....

Nearly half of surveyed parents likely to modify ADHD medication over summer.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Nearly half of parents (46%) of kids with attention-deficit/hyperactivity disorder (ADHD) said they planned to reduce or eliminate their children's ADHD medication this summer, even though nearly 80%...

Oral efficacy confirmed for autoimmune disease therapeutics.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- ProMetic Life Sciences Inc. (PLI) announced that its Therapeutic Unit has confirmed the oral efficacy of two of its new compounds for the treatment of chronic inflammatory conditions. "In less than...

Microbia attains milestone in Precision Engineering technology alliance.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Microbia, Inc., and Ranbaxy Laboratories, Ltd., announced the successful pilot-plant validation of a higher-yielding biomanufacturing process using Microbia's Precision Engineering technology. ...

RG2133 appears safe and clinically effective for bipolar disorder, depression.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Repligen Corporation (RGEN) announced the results of a phase I, open-label clinical trial of RG2133, a prodrug of uridine, designed to assess the impact of uridine in patients with either bipolar...

Biomarker study focuses on indicators of Herceptin responsiveness.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Aclara BioSciences (Nasdaq: ACLA) and the Tokyo Metropolitan Institute of Medical Science (Rinshoken) have entered into an agreement to collaborate on a study to evaluate breast cancer patient samples...

Bonefos increases survival in primary operable breast cancer patients.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Data presented at the 40th Annual American Society of Clinical Oncology Meeting showed that oral clodronate (Bonefos), when administered daily for 2 years, decreased the incidence of bone metastases and...

Gemzar/Taxol vs Taxol alone improves survival in breast cancer study patients.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- New interim data show that metastatic breast cancer patients experienced a promising improvement in survival when treated with a Gemzar/Taxol combination compared to patients treated with Taxol alone, a...

Raloxifene, exemestane may provide postmenopausal breast cancer risk reduction.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Attendees at the 40th annual meeting of the Association of Clinical Oncologists were updated on the serum estrogen receptor modulator (SERM) raloxifene and the aromatase inhibitor (AI) exemestane, with...

Results reported in trial of Abraxane for advanced breast cancer patients.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Abraxis Oncology, a division of American Pharmaceutical Partners, Inc., (APP, APPX) said that results from a 106 patient phase II study of Abraxane in patients with advanced breast cancer whose disease...

Significant survival advantage reported in phase III trial of Theratope.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Biomira, Inc., (BIOM, BRA) of Edmonton, Alberta, Canada, announced that an exploratory analysis showed a statistically significant survival advantage for women in the hormonal therapy subset of patients...

Study investigates resistance to tamoxifen and possible way to reverse it.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- A new study has found a possible mechanism for tamoxifen resistance in breast cancer and provides evidence that another cancer drug - gefitinib (AstraZeneca brand name: Iressa) - may be able to restore...

Study: Common management practices can cost typical biotech company $2B.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Mardis, Aibel and Associates, LLC, a biotechnology management consulting firm, has released study results demonstrating a 20 percentage-point gap in the average annual growth rate in market value...

Biotech company announces entry into European surgical devices market.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Alltracel Pharmaceuticals Plc, (AP.L) announced its entry into the post and inter operative surgical market with the third quarter launch by one of the world's leading medical device companies of an...

Biotech company provides update on planned equity offering, Nasdaq listing.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- GPC Biotech, AG, provided further details on its planned equity offering and Nasdaq listing. The company made a public filing of a registration statement related to the planned offering with the...

CompuMed maker announces appointment of new auditors and election of new CFO.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Milestone Scientific, Inc., (AMS) has engaged Eisner, LLP, as its new independent auditors. Eisner, LLP, will replace J.H. Cohn, LLP, the company's former independent auditors. The company also...

Isis gains full ownership of Orasense and HepaSense subsidiaries.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Isis Pharmaceuticals, Inc., (ISIS) announced that it has entered into an agreement with a subsidiary of Elan Corp., plc, to acquire Elan's minority interest in Orasense and HepaSense, joint ventures...

Results of AVR118 phase I/II clinical program presented at ASCO.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Advanced Viral Research Corp. (ADVR) announced that the company presented interim results of its phase I/II clinical program with its flagship product, AVR118, at The American Society of Clinical...

Device firm reaches agreement with FDA on trial of ComfortScan system.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Dobi Medical International, Inc., (DBMI) announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding the clinical study the company will conduct as its final step...

Company initiates phase II corporate clinical program for KRX-0401 (Perifosine).
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Keryx Biopharmaceuticals, Inc., (KERX) announced the initiation of a corporate-sponsored clinical program for KRX-0401 (Perifosine), a novel, oral, AKT inhibitor for the treatment of cancer. In...

FDA grants fast track designation for MedPulser Electroporation Therapy System.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Genetronics Biomedical Corp. (GEB) has been granted a fast track designation by the U.S. Food and Drug Administration for its MedPulser Electroporation System clinical development program for patients...

Genotyping helps determine appropriate Quinamed dose in cancer study patients.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Results of a phase I/II trial that used patient genotyping to determine dosing of Quinamed (amonafide dihydrochloride), an experimental cancer drug under development by ChemGenex Therapeutics, were...

NCI awards grant for brain cancer collaboration.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Intradigm Corp. has been awarded a phase I small business technology transfer program grant by the National Cancer Institute to support its technology transfer and collaboration with Prof. A. James...

Pin1 enzyme may lead to development of more precise cancer treatments.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Pintex Pharmaceuticals, Inc., reported that its work on the Pin1 enzyme could lead to the development of a number of diagnostics and therapies that could provide more precise treatment of breast,...

Results from phase I/II cancer trials with rhLF presented at ASCO.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- The Department of Hematology/Oncology at the Veterans Affairs Medical Center (VAMC), Houston, Texas, and Agennix Inc., disclosed results from two phase I/II cancer trials with oral recombinant human...

Updated phase II lung cancer clinical trial results presented at ASCO.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Genaera Corp. (GENR) announced updated interim safety and efficacy results for its antiangiogenic drug, squalamine, in its phase IIb non-small cell lung cancer (NSCLC) clinical trial. The...

34% of cardiovascular drugs' marketing budgets spent on launch activities.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Pharmaceutical companies allocate 34% of new cardiovascular drugs' total marketing budgets for launch activities, according to a recent study conducted by pharmaceutical intelligence firm Cutting Edge...

Data from phase III trial of radiation sensitizer presented at ASCO.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Allos Therapeutics, Inc., (ALTH) announced that results from its phase III clinical trial of the investigational radiation sensitizer RSR13 (efaproxiral) in patients with brain metastases were presented...

Patient recruitment identified as leading cause of clinical trial delays.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Clinical affairs executives rank patient recruitment as the number one area where the industry can accelerate clinical trials, according to Cutting Edge Information's newest report, "Accelerating...

Agreement means new stem cell lines available for research.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- New stem cell lines to be made freely available to researchers searching for cures to diseases such as stroke, cancer, diabetes, and heart disease will be developed in Melbourne the Victorian Premier,...

Agreement signed for integrated software to life science researchers.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Biomax Solutions, Inc., of Falmouth, Massachusetts, and Geospiza, Inc., of Seattle, Washington, have announced the formation of an alliance and reseller relationship to integrate bioinformatics systems...

Agreement signed to develop IV terlipressin for Type 1 hepato-renal syndrome.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- ESP Pharma, Inc., a niche pharmaceutical company focused on the acquisition, marketing, and late-stage development of life-saving acute-care therapeutics, announced that it has entered into an agreement...

Companies to offer DNA sequencing instruments, analysis software as a package.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Geospiza and AME Bioscience announced an international sales and support agreement to deliver low cost, integrated software and sequencing instrument solutions to life science researchers worldwide. ...

Deal signed for distribution, marketing of bone graft substitutes.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Blackstone Medical, Inc., announced that it has reached an agreement with Berkeley Advanced Biomaterials, Inc., to distribute and market their synthetic bone graft substitutes for spine surgery...

Manufacturing agreement signed with Lilly.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Elan Corporation, plc, announced that it has entered into a manufacturing and supply agreement with Eli Lilly and Company (Lilly) under which Elan will supplement Lilly's manufacture of duloxetine...

Partnership with AstraZeneca intended to identify biomarkers.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Cell Signaling Technology, Inc., (CST) announced an agreement with AstraZeneca to perform a pilot study profiling select AstraZeneca compounds with CST's Global Phospho-Signature technology to discover...

Strategic deal for copolymer technologies with SynthRx closed.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- CytRx Corporation (CYTR) announced that it has closed its deal to license its copolymer technologies, including Flocor, Opti-Vax and related anti-infective products, on an exclusive basis to SynthRx,...

Therapeutic antibody program acquired from Sunol Molecular.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Caprion Pharmaceuticals announced the acquisition of therapeutic antibodies currently in phase I clinical trials for the treatment of Hemolytic Uremic Syndrome (HUS) resulting from E. coli infection, as...

Worldwide rights acquired for MRI-safe ceramic motor.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Biophan Technologies, Inc., (BIPH) has signed an exclusive, worldwide distribution agreement with Victor, New York-based New Scale Technologies, Inc., for distribution of New Scale's ceramic "SQUIGGLE...

Positive data reported for CoFactor, VEGF antibody, 5-FU combination.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Adventrx Pharmaceuticals, Inc., (ANX) announced positive results using CoFactor in combination with 5-fluorouracil (5-FU) and an antibody-based inhibitor of vascular endothelial growth factor...

Trials show Erbitux provides new options for patients with colorectal cancer.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Merck KGaA, Darmstadt, Germany, is encouraged by the results of two clinical trials with Erbitux (cetuximab) in metastatic colorectal cancer (CRC). Data presented at the 40th Annual Meeting of the...

NutraCea signs estimated $5 million private label agreement.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- NutraCea (NTRZ), a nutraceutical company whose products are based on proprietary stabilized rice bran and its derivatives, announced that it has signed a licensing agreement with Nussentials, Inc. - a...

Progress reported in development of non-viral gene transfer aerosol product.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Copernicus Therapeutics, Inc., presented data at the 7th Annual Meeting of the American Society of Gene Therapy showing that compacted DNA nanoparticles can be successfully formulated as aerosol mists...

ADA initiates research program to prevent type 1 diabetes.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- The American Diabetes Association (ADA) announced at the ADA's 64th Scientific Sessions a collaboration with Entelos, Inc., to initiate a cutting-edge research program aimed at preventing type 1...

In silico animal model built for type 1 diabetes.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Entelos, a biotech company pioneering in silico research and the use of computer models to advance pharmaceutical research and development, announced that it will develop an in silico model of the...

Actos shows sustained efficacy over 2-year period.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Long-term studies using the oral antidiabetic drug Actos (pioglitazone HCl) alone, and in combination with other oral antidiabetic medications, found that it provided sustained improvements in glycemic...

First Sucanon production order completed.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Robert Rieveley, president of Biotech Holdings (BIO.V; BIOHF) announced that the company has completed the first production order of its Sucanon diabetes drug. "I am pleased to report that our first...

Lipitor reduces heart attacks and strokes in study patients with diabetes.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Pfizer Inc's cholesterol-lowering medicine, Lipitor, significantly reduced heart attacks and strokes in patients with diabetes, according to data presented from the largest study specifically designed...

Companies sign distribution agreement for NMP22 Test Kit.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Matritech, Inc., (MZT), a developer of protein-based diagnostic products for the early detection of cancer, and Wampole Laboratories, LLC, a wholly owned subsidiary of Inverness Medical Innovations,...

Drug development services provider receives CDISC certification.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Quintiles Transnational Corp. has been certified as a CDISC Registered Solutions Provider for managing data submitted for the approval of new medicines. CDISC - the Clinical Data Interchange...

Improved throughput protein precipitation method presented.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Argonaut Technologies (AGNT) presented a poster on a new protein precipitation filterplate at the 2004 American Society of Mass Spectrometry (ASMS) conference in Nashville, Tennessee. In the...

New findings on drug composition may allow better preservation in heat.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- A spoonful of sugar may help the medicine go down, but it may take only a thin coating of freeze-dried sugar to keep insulin, vaccines and other heat-sensitive, protein-based drugs working reliably even...

Online resource helps researchers seeking to build new bioactive compounds.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- It's not exactly a "pinch of this and a dash of that" kind of guide. Yet the online resource for making molecules recently unveiled by the Center for Chemical Methodology and Library Development at...

Rabies has potential use in vaccines for other infectious diseases.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Scientists at Jefferson Medical College have literally "fused" a part of a rabies virus protein to another foreign protein, resulting in a more robust immune response in animals than with the protein...

Data show Ethyol reduces radiation-induced dry mouth.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Data presented from a phase III clinical trial involving 303 head and neck cancer patients showed that Ethyol (amifostine) reduced the incidence of moderate-to-severe dry mouth (xerostomia) in patients...

Studies show that ACTOS has positive effects on dyslipidemia, insulin resistance.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Two clinical studies presented at the American Diabetes Association's (ADA) Scientific Sessions showed that ACTOS (pioglitazone HCl) has favorable effects on dyslipidemia and insulin resistance. ...

Co-administration of PT-141 and Viagra yields positive results in ED study.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Palatin Technologies, Inc., (PTN) announced positive results from a clinical study evaluating the co-administration of PT-141 and Viagra. The purpose of the PT-141 and Viagra co-administration...

Diabetic men are at greater risk for developing erectile dysfunction.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Men being treated for diabetes are three times more likely to have erectile dysfunction (ED) than men in the general population. In addition, more than 50% of diabetic men develop ED within 10...

AQ4N well tolerated in first phase I report.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- KuDOS Pharmaceuticals (KuDOS) and Novacea, Inc., announced the publication of interim results from a phase I dose escalation study of AQ4N. The results were published in the Proceedings of the 2004...

FDA grants approval for ciprofloxacin in eye conditions.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Bausch & Lomb (BOL) has received U.S. Food and Drug Administration approval of the company's Abbreviated New Drug Application (ANDA) to manufacture and sell ciprofloxacin ophthalmic solution USP, 0.3%....

Biopharmaceutical company reports fourth quarter financial results.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Repligen Corporation (RGEN) reported results for the fourth quarter and fiscal year ended March 31, 2004. Total revenue for the fiscal year ended March 31, 2004, was $6,914,000 compared to total...

Biopharmaceutical company sells $25M in convertible notes.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- CV Therapeutics, Inc., (CVTX) announced that the initial purchasers of CV Therapeutics' 2.75% senior subordinated convertible notes due 2012 have exercised their option to purchase an additional $25.0...

Biopharmaceutical firm exercises underwriters' over-allotment option.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Alnylam Pharmaceuticals, Inc., (ALNY) announced that the underwriters of its recent initial public offering of 5,000,000 shares of common stock have exercised in full their over-allotment option to...

Pharmaceutical company acquires remaining interest in subsidiary.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Depomed, Inc., (DEPO) announced that it has acquired Elan's 19.9% stake in Depomed's 80.1% owned subsidiary, Depomed Development, Ltd., (DDL) for $50,000. The acquisition gives Depomed 100%...

Pharmaceutical company amends 2004 stock option plan proposal.
July 5, 2004... 2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Biovail Corporation (BVF, BVF) announced that the company's board of directors has amended its proposal to adopt a new stock option plan as described in the company's 2004 Proxy Statement, subject to...